Navigation Links
Atrium Medical Corporation Announces First Implant of First-in-Man CINATRA(TM) Voclosporin Coated Coronary Stent

HUDSON, N.H., June 9 /PRNewswire/ -- Atrium Medical announced today that it has begun enrollment of the first patients for their CONFIRM 1, First-in-Man (FIM) drug eluting coronary stent clinical trial. Atrium's European FIM clinical trial study is evaluating Atrium's CINATRA(TM) voclosporin coated coronary stent system.

This First-in-Man trial is a prospective, multi-center, single blind, randomized, controlled study using the CINATRA(TM) voclosporin coated coronary stent system, which will be compared to Atrium's CINATRA(TM) bare metal coronary stent (BMS) platform. This first use study of voclosporin on an implantable medical device will enroll 100 patients, and will be conducted at seven hospitals in Belgium with Glenn Van Langenhove, MD, PhD of Middelheim Hospital, Antwerp, as the study's Principal Investigator. The primary endpoint of the trial is to evaluate the safety and performance of the CINATRA(TM) voclosporin coated coronary stent system and the CINATRA(TM) BMS coronary stent system in patients with de novo coronary artery disease. Patient outcomes, in addition to drug coated stent performance, will be assessed by measuring Late Lumen Loss, in-stent and in-segment lumen loss measurements at six months following implantation.

After many years of pre-clinical testing, Atrium is very excited to be able to study the new CINATRA(TM) coronary stent platform with voclosporin, a promising new drug, and the company's all natural O3FA coating technology that merges the desirable safety benefits of a bare metal stent with the clinical advantages of a bio-absorbable Omega 3 fatty acid coating. Use of Atrium's patented Omega 3 coating platform, together with its novel drug compound has created a new class of patient treatment options who require a drug eluting coronary stent. Interventional cardiologists and patients alike have been waiting for a new technology that delivers the effectiveness of a drug eluting stent with a safer, more natural, non-polymer coating platform resulting in a well healed implant shortly after insertion.

About the CINATRA(TM) Voclosporin Drug Eluting Coronary Stent System

The CINATRA(TM) voclosporin coated coronary stent system is an advanced cobalt chromium balloon expandable stent, mounted on a low profile rapid exchange catheter. Atrium's stent and balloon are both coated with Atrium's proprietary Omega 3 fatty acid coating technology, providing a more uniform bio-absorbable delivery vehicle for its anti-inflammatory compound, voclosporin.

About Voclosporin

Voclosporin is a next generation calcineurin inhibitor and was selected for its desired anti-inflammatory properties in the vascular system. Voclosporin is a product of Edmonton-based Isotechnika Inc., licensed exclusively to Atrium Medical in 2005 for use with implantable medical devices.

About Atrium

Atrium's vast expertise in medical device technologies for the treatment of cardiovascular disease, hernia and adhesion prevention has brought a number of breakthrough advances in several diversified healthcare markets including interventional cardiology and radiology, chest trauma care and thoracic drainage, vascular surgery, and soft tissue repair. Maintaining a commitment to the latest ISO13485 Quality Standards, state-of-the-art manufacturing and automation, cell biology and biomaterial discovery programs, Atrium continues to excel in those healthcare segments that require more advanced surgical intervention for improvements in patient outcome. For more information, call 800-370-7899 or visit

SOURCE Atrium Medical
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. OxyBand Technologies, Inc. Hires a Leader in Medical Technology as Chief Technology Officer
2. Valor Medical Reports Early Clinical Results of New Technology to Treat Cerebral Aneurysms
3. Prescient Medical, Inc. Achieves Successful Clinical Debut of vProtect(TM) Luminal Shield
4. Sahajanand Medical Technologies PAINT Trial Results Support Safety and Efficacy of the Infinnium and Supralimus Stents
5. Join NPRs David Ewing Duncan, Author Jessica Queller and a Panel of Medical and Legal Experts in a 90-Minute Webcast on Genetic Testing, Genomic Medicine and Breast & Ovarian Cancer
6. Top Academic Medical Centers, Research Institutions, and Partners Gather, Share Experiences and Success Stories at Velos eResearch Annual Meeting
7. Globus Medical Completes Enrollment Of SECURE(R)-C Cervical Artificial Disc Clinical Trial
8. New Data Show High Frequency of Medical Claims for Gastrointestinal Events by Patients on Antiplatelet Therapy
9. Quantum Immunologics, Inc. and the South Alabama Medical Science Foundation Announce an Early Clinical Evaluation of a Novel Immuno-therapeutic Vaccine for Treating Advanced Human Breast Carcinomas
10. Delcath Expands Phase III Trial for Metastatic Melanoma to Include University of Maryland Medical Center
11. Tepha Announces First Human Usage of Medical Devices Derived from New Class of Resorbable Polymers
Post Your Comments:
(Date:12/1/2015)... VERONA, Va. , Dec. 1, 2015 /PRNewswire/ ... today unveiled a new corporate logo and brand ... in the design and engineering of bladed products ... --> --> Serving ... fiber, glass, and auto glass equipment, AccuTEC,s product ...
(Date:12/1/2015)... --> --> ... Acid Labeling Market by Product (Reagents & Kits, Services), ... Vitro Transcription, Reverse Transcription, End Labeling), by Region - ... market is expected to reach USD 1,925.7 Million by ... a CAGR of 8.65%. Browse 77 market ...
(Date:12/1/2015)... December 1, 2015 Russia has ... trials. 70% of new drugs registered in Europe ... . --> Russia has always been a ... new drugs registered in Europe in 2015 were ... Russia has always been a country of ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... December 01, 2015 , ... ... continue the expansion of the company’s growing product line of food safety and ... tshawytscha) and Sockeye (Oncorhynchus nerka) – allow InstantLabs to offer fast, reliable species ...
(Date:12/1/2015)... ... 2015 , ... It’s official: Tattoo taboo is a thing of the past. ... Millennials (a whopping one in three aged 18 to 25 is inked). As tattoos ... their ink. In fact, RealSelf , the world’s largest community for learning and ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... of adjunctive imaging is the focus of numerous abstracts accepted for presentation here, ... 4, 2015. Nine abstracts highlight the use of Volpara Solutions’ quantitative breast ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... Inc. (“Visage”), a wholly owned subsidiary of Pro Medicus Ltd. (ASX: PME), has ... the Radiological Society of North America (RSNA) 2015 annual meeting through December 3 ...
(Date:12/1/2015)... ... December 01, 2015 , ... McLean, VA., December ... a fixed price per sprint agile development contract to support the National Geospatial-Intelligence ... five years, provides software engineering, infrastructure, as well as operations and sustainment support ...
Breaking Medicine News(10 mins):